News

This designation aims to expedite the development and review of the therapy for paediatric patients with early-stage type 1 diabetes carrying the HLA DR3-DQ2 genotype. The status aids

Champion VC and LRM founder and CEO Dr Samuel Lynch spearheaded the financing round. This funding will support the company’s efforts to leverage its patented pure platelet-derived growth

The new line, representing an investment of nearly €6.6m ($7.1m), is located at the Life Science Center in Nantong. This development is aimed at meeting the increasing local

SPS is a rare, debilitating neurological autoimmune disorder characterised by muscle stiffness and spasms. Kyverna’s KYV-101 is an autologous, fully human CD19 CAR T-cell therapy designed to address

The deal, which was announced in May 2024, includes an upfront cash payment of $1.3bn and $1.7bn in milestone payments on meeting developmental, regulatory and commercial goals. Under

The approval of Leqembi (generic name: Lecanemab) in Israel marks a significant milestone, as Israel becomes the sixth territory to endorse the drug for Alzheimer’s treatment after the

Ambien CR (zolpidem tartrate extended-release tablets) is intended for the short-term management of insomnia, which is manifested by challenges in initiating sleep and/or maintaining sleep continuity. Ambien (zolpidem

This product different from other versions of fosaprepitant as it is free from Polysorbate 80 and requires no reconstitution or dilution, simplifying administration directly from the vial utilising

An armoured allogeneic “off-the-shelf”gamma delta CAR T cell therapy, ADI-270 targets CD70-positive cancers. ADI-270 is engineered to target CD70 by using CD27 as the natural receptor binding moiety.